Viridian Therapeutics, Inc. (VRDN) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $19.04 (-4.25%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Laura Chico | Wedbush | $31.00 | +62.8% |
| Feb 26, 2026 | Kelly Shi | Jefferies | $45.00 | +136.3% |
| Jan 28, 2026 | Gavin Clark-Gartner | Evercore ISI | $45.00 | +136.3% |
| Jan 20, 2026 | Gavin Clark-Gartner | Evercore ISI | $44.00 | +131.1% |
| Nov 5, 2025 | Alex Thompson | Stifel Nicolaus | $48.00 | +152.1% |
| Oct 21, 2025 | Douglas Tsao | H.C. Wainwright | $34.00 | +78.6% |
| Nov 12, 2024 | Alex Thompson | Stifel Nicolaus | $20.50 | +7.7% |
| Sep 13, 2024 | Gregory Renza | RBC Capital | $22.00 | +15.5% |
| Sep 11, 2024 | Serge Belanger | Needham | $19.00 | -0.2% |
| Sep 11, 2024 | Kalpit Patel | B.Riley Financial | $22.00 | +15.5% |
| Sep 10, 2024 | Alex Thompson | Stifel Nicolaus | $20.00 | +5.0% |
| Sep 10, 2024 | Julian Harrison | BTIG | $28.00 | +47.1% |
| Aug 14, 2024 | Richard Law | Goldman Sachs | $25.00 | +31.3% |
| Jun 11, 2024 | Gregory Renza | RBC Capital | $17.50 | -8.1% |
| Jun 11, 2024 | Julian Harrison | BTIG | $23.00 | +20.8% |
| Jun 10, 2024 | Andy Chen | Wolfe Research | $14.50 | -23.8% |
| Jun 6, 2024 | Richard Law | Goldman Sachs | $11.50 | -39.6% |
| May 9, 2024 | Leland Gershell | Oppenheimer | $15.50 | -18.6% |
| May 9, 2024 | Douglas Tsao | H.C. Wainwright | $13.50 | -29.1% |
| May 9, 2024 | Kalpit Patel | B.Riley Financial | $20.00 | +5.0% |
Top Analysts Covering VRDN
VRDN vs Sector & Market
| Metric | VRDN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.09 | 2.25 | 2.42 |
| Analyst Count | 23 | 8 | 19 |
| Target Upside | +91.8% | +16366.0% | +18.0% |
| P/E Ratio | -3.37 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $7M | $17M | $28M | 4 |
| 2026-12-31 | $13M | $32M | $51M | 4 |
| 2027-03-31 | $19M | $48M | $77M | 4 |
| 2027-06-30 | $26M | $64M | $102M | 3 |
| 2027-09-30 | $31M | $78M | $125M | 3 |
| 2027-12-31 | $51M | $127M | $203M | 3 |
| 2028-12-31 | $594M | $598M | $602M | 11 |
| 2029-12-31 | $417M | $860M | $1.78B | 5 |
| 2030-12-31 | $538M | $1.11B | $2.30B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.76 | $-0.99 | $-0.22 | 3 |
| 2026-12-31 | $-1.58 | $-0.89 | $-0.19 | 6 |
| 2027-03-31 | $-1.32 | $-0.74 | $-0.16 | 3 |
| 2027-06-30 | $-1.20 | $-0.68 | $-0.15 | 5 |
| 2027-09-30 | $-1.09 | $-0.61 | $-0.14 | 3 |
| 2027-12-31 | $-0.58 | $-0.33 | $-0.07 | 6 |
| 2028-12-31 | $-10.97 | $-0.12 | $9.27 | 10 |
| 2029-12-31 | $0.59 | $1.80 | $4.30 | 4 |
| 2030-12-31 | $1.05 | $3.17 | $7.57 | 4 |
Frequently Asked Questions
What is the analyst consensus for VRDN?
The consensus among 23 analysts covering Viridian Therapeutics, Inc. (VRDN) is Buy with an average price target of $36.88.
What is the highest price target for VRDN?
The highest price target for VRDN is $48.00, set by Alex Thompson at Stifel Nicolaus on 2025-11-05.
What is the lowest price target for VRDN?
The lowest price target for VRDN is $11.50, set by Richard Law at Goldman Sachs on 2024-06-06.
How many analysts cover VRDN?
23 analysts have issued ratings for Viridian Therapeutics, Inc. in the past 12 months.
Is VRDN a buy or sell right now?
Based on 23 analyst ratings, VRDN has a consensus rating of Buy (2.09/5) with a +91.8% upside to the consensus target of $36.88.
What are the earnings estimates for VRDN?
Analysts estimate VRDN will report EPS of $-0.99 for the period ending 2026-09-30, with revenue estimated at $17M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.